JP2014240404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014240404A5 JP2014240404A5 JP2014154372A JP2014154372A JP2014240404A5 JP 2014240404 A5 JP2014240404 A5 JP 2014240404A5 JP 2014154372 A JP2014154372 A JP 2014154372A JP 2014154372 A JP2014154372 A JP 2014154372A JP 2014240404 A5 JP2014240404 A5 JP 2014240404A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- regulatory
- cell epitope
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89834707P | 2007-01-30 | 2007-01-30 | |
| US60/898,347 | 2007-01-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011247226A Division JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064298A Division JP6472476B2 (ja) | 2007-01-30 | 2017-03-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014240404A JP2014240404A (ja) | 2014-12-25 |
| JP2014240404A5 true JP2014240404A5 (enExample) | 2015-02-12 |
| JP6121369B2 JP6121369B2 (ja) | 2017-04-26 |
Family
ID=39674696
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548278A Expired - Fee Related JP4866467B2 (ja) | 2007-01-30 | 2008-01-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2011247226A Expired - Fee Related JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2014154372A Expired - Fee Related JP6121369B2 (ja) | 2007-01-30 | 2014-07-30 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2017064298A Expired - Fee Related JP6472476B2 (ja) | 2007-01-30 | 2017-03-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2019008352A Pending JP2019089793A (ja) | 2007-01-30 | 2019-01-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021011596A Withdrawn JP2021073255A (ja) | 2007-01-30 | 2021-01-28 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072446A Pending JP2021107443A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072455A Pending JP2021107444A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2022155804A Pending JP2022177270A (ja) | 2007-01-30 | 2022-09-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2024033497A Pending JP2024059975A (ja) | 2007-01-30 | 2024-03-06 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009548278A Expired - Fee Related JP4866467B2 (ja) | 2007-01-30 | 2008-01-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2011247226A Expired - Fee Related JP5643739B2 (ja) | 2007-01-30 | 2011-11-11 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017064298A Expired - Fee Related JP6472476B2 (ja) | 2007-01-30 | 2017-03-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2019008352A Pending JP2019089793A (ja) | 2007-01-30 | 2019-01-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021011596A Withdrawn JP2021073255A (ja) | 2007-01-30 | 2021-01-28 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072446A Pending JP2021107443A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2021072455A Pending JP2021107444A (ja) | 2007-01-30 | 2021-04-22 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2022155804A Pending JP2022177270A (ja) | 2007-01-30 | 2022-09-29 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
| JP2024033497A Pending JP2024059975A (ja) | 2007-01-30 | 2024-03-06 | 調節性ｔ細胞エピトープ、組成物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (18) | US7884184B2 (enExample) |
| EP (13) | EP2423219B1 (enExample) |
| JP (10) | JP4866467B2 (enExample) |
| KR (3) | KR101722305B1 (enExample) |
| CN (4) | CN101687912B (enExample) |
| AT (1) | ATE525392T1 (enExample) |
| AU (1) | AU2008211227B2 (enExample) |
| CA (6) | CA2677073C (enExample) |
| IL (3) | IL200129A (enExample) |
| MX (3) | MX2009008230A (enExample) |
| WO (1) | WO2008094538A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2423219B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| DE102007030904A1 (de) * | 2007-07-03 | 2009-02-05 | Pharis Biotec Gmbh | Humanes zirkulierendes antivirales Albumin-Fragment (ALB-408) und seine Verwendung |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US9402916B2 (en) | 2011-03-17 | 2016-08-02 | The University Of Birmingham | Re-directed immunotherapy |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| CN104114180B (zh) * | 2011-12-13 | 2017-01-18 | 法国国家科学研究中心 | 修饰肽及其用于治疗自体免疫疾病的用途 |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| JP6740127B2 (ja) * | 2013-12-06 | 2020-08-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 新生物ワクチン用製剤 |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| WO2016054114A1 (en) | 2014-09-29 | 2016-04-07 | The Regents Of The University Of California | Compositions for expanding regulatory t cells (treg), and treating autoimmune and inflammatory diseases and conditions |
| US10213482B2 (en) | 2014-12-12 | 2019-02-26 | Immupharma France Sa | Methods of treating chronic inflammatory diseases |
| AU2016215604B2 (en) | 2015-02-02 | 2020-08-13 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes |
| US20180179256A1 (en) * | 2015-05-04 | 2018-06-28 | Epivax, Inc. | Modified H7 Hemagglutinin Glycoprotein of the Influenza A/Shanghai/2/2013 H7 Sequence |
| WO2016179099A1 (en) | 2015-05-04 | 2016-11-10 | Epivax, Inc. | Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence |
| EP3903818A1 (en) | 2015-11-19 | 2021-11-03 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| PL238939B1 (pl) * | 2016-11-02 | 2021-10-18 | Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Im Ludwika Hirszfelda We Wrocławiu | Peptyd immunosupresyjny i jego zastosowania |
| US11441122B2 (en) | 2017-10-05 | 2022-09-13 | Epivax Inc. | Regulatory T cell epitopes |
| EP3622962A1 (en) * | 2018-09-14 | 2020-03-18 | advanceCOR GmbH | Short cyclic peptides for the treatment of graves' disease |
| WO2020227233A2 (en) * | 2019-05-03 | 2020-11-12 | Richard Guilhem | Neoantigens in cancer |
| JP2023519347A (ja) * | 2020-03-27 | 2023-05-10 | ビオテスト・アクチエンゲゼルシャフト | 少なくとも１つの制御性ｔ細胞活性化エピトープを含むタンパク質 |
| US11911414B2 (en) | 2020-03-27 | 2024-02-27 | Epivax Inc. | Regulatory T cell epitopes |
| CN111856020B (zh) * | 2020-06-19 | 2022-09-27 | 南方医科大学南方医院 | 乙型肝炎病毒（hbv）特异性t细胞检测方法及其应用 |
| JP2023538002A (ja) * | 2020-08-13 | 2023-09-06 | エピバックス・インコーポレーテッド | 制御性ｔ細胞エピトープ |
| CA3193819A1 (en) * | 2020-09-25 | 2022-03-31 | Anne De Groot | Retro-inverso regulatory t cell epitopes |
| JP7852032B2 (ja) * | 2021-07-16 | 2026-04-27 | デベヴェ・テクノロジーズ | 対象におけるカシュー耐性を増大させるための免疫治療法 |
| WO2024240690A2 (en) | 2023-05-19 | 2024-11-28 | Numab Therapeutics AG | Antibody variable domains and antibodies having decreased immunogenicity |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| FR2556219B1 (fr) | 1983-12-07 | 1987-06-26 | Merieux Inst | Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines |
| GB8725529D0 (en) † | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| FR2686899B1 (fr) † | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5817308A (en) * | 1994-02-14 | 1998-10-06 | University Of Rochester | Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance |
| DE4425115A1 (de) | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
| US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| ATE267610T1 (de) | 1996-03-20 | 2004-06-15 | Immunomedics Inc | Glykosylierte igg antikörper |
| DE69840723D1 (de) * | 1997-02-11 | 2009-05-20 | Immunomedics Inc | Stimulation einer immunantwort durch antikörper, welche mit dem alpha-galaktosylepitop markiert sind |
| AU7266698A (en) * | 1997-04-30 | 1998-11-24 | Enzon, Inc. | Polyalkylene oxide-modified single chain polypeptides |
| US6953675B2 (en) | 1997-11-06 | 2005-10-11 | Immunomedics, Inc. | Landscaped antibodies and antibody fragments for clinical use |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1180159B1 (en) | 1999-05-28 | 2008-09-03 | Targeted Genetics Corporation | Methods and compositions for lowering the level of tumor necrosis factor (tnf) in tnf-associated disorders |
| US6445840B1 (en) | 1999-05-28 | 2002-09-03 | Omm, Inc. | Micromachined optical switching devices |
| EP1274720A4 (en) † | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | FUSION PROTEINS CONTAINING ALBUMIN |
| CA2415902A1 (en) † | 2000-07-10 | 2002-01-17 | Xencor | Protein design automation for designing protein libraries with altered immunogenicity |
| WO2002074783A2 (en) * | 2001-03-15 | 2002-09-26 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
| WO2002079415A2 (en) † | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| US7524502B2 (en) * | 2001-11-12 | 2009-04-28 | Merck Patent Gmbh | Modified anti-TNF alpha antibody |
| CA2469078A1 (en) † | 2001-12-05 | 2003-06-12 | Circassia Limited | Immunotherapeutic methods and systems |
| EP1463752A4 (en) † | 2001-12-21 | 2005-07-13 | Human Genome Sciences Inc | ALBUM INFUSION PROTEINS |
| PT1463751E (pt) † | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| CA2475382A1 (en) † | 2002-02-07 | 2003-08-14 | Delta Biotechnology Limited | Albumin-fused anti-angiogenesis peptides |
| US7317091B2 (en) * | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| AU2003243315B8 (en) | 2002-05-24 | 2009-05-21 | Medtronic, Inc. | Peptide amidation process |
| ATE472556T1 (de) * | 2002-12-02 | 2010-07-15 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| CN1511958A (zh) * | 2002-12-31 | 2004-07-14 | 王小宁 | 一种筛选人组织相容性抗原(hla)的t细胞表面抗原肽的体系,及其在制备mhc-抗原肽多聚体中的应用 |
| CA2513213C (en) † | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| JP2007528723A (ja) * | 2003-08-22 | 2007-10-18 | メディミューン，インコーポレーテッド | 抗体のヒト化 |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| EP1701979A2 (en) * | 2003-12-03 | 2006-09-20 | Xencor, Inc. | Optimized antibodies that target the epidermal growth factor receptor |
| EP2857418B1 (en) | 2004-02-06 | 2017-07-26 | University of Massachusetts | Antibodies against Clostridium difficile toxins and uses thereof |
| JP5010923B2 (ja) † | 2004-02-09 | 2012-08-29 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合蛋白質 |
| PL1737961T3 (pl) * | 2004-03-19 | 2013-12-31 | Merck Patent Gmbh | Zmodyfikowane białka bouganiny, cytotoksyny i sposoby oraz ich zastosowania |
| CA2561686C (en) * | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CN1993378A (zh) | 2004-08-03 | 2007-07-04 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| AP2007003893A0 (en) | 2004-08-03 | 2007-02-28 | Transtech Pharma Inc | Rage fusion proteins and methods of use |
| CU23504A1 (es) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| US7488804B2 (en) † | 2005-02-02 | 2009-02-10 | The Regents Of The University Of California | Modified fusion molecules for treatment of allergic disease |
| EP2388271A3 (en) * | 2005-02-03 | 2012-08-01 | Antitope Limited | Human Antibodies and Proteins |
| EP1899379B1 (en) | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| JP2009504157A (ja) † | 2005-08-12 | 2009-02-05 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | アルブミン融合タンパク質 |
| CN100349921C (zh) * | 2005-11-17 | 2007-11-21 | 中国人民解放军第四军医大学 | 破伤风毒素t细胞表位多肽与人b淋巴细胞刺激因子融合蛋白及其制备 |
| PL2253644T3 (pl) * | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
| CN103073639A (zh) * | 2006-03-17 | 2013-05-01 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
| GB0605735D0 (en) | 2006-03-22 | 2006-05-03 | Immunobiology Ltd | Composition and method for mediating an immune response |
| AU2007258609B2 (en) † | 2006-06-07 | 2013-01-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AT503861B1 (de) † | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von t-zell-rezeptoren |
| JP5244103B2 (ja) | 2006-08-09 | 2013-07-24 | ホームステッド クリニカル コーポレイション | 器官特異的蛋白質およびその使用方法 |
| EP2423219B1 (en) * | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| BRPI0812465A2 (pt) | 2007-06-08 | 2014-12-02 | Dow Global Technologies Inc | Expressão de fragmento de anticorpo solúvel por truncação de domínio ch1 |
-
2008
- 2008-01-29 EP EP20110177609 patent/EP2423219B1/en not_active Not-in-force
- 2008-01-29 EP EP20120153174 patent/EP2450371B1/en not_active Not-in-force
- 2008-01-29 CN CN200880011016.5A patent/CN101687912B/zh not_active Expired - Fee Related
- 2008-01-29 AU AU2008211227A patent/AU2008211227B2/en not_active Ceased
- 2008-01-29 CN CN202011190692.2A patent/CN112279911A/zh active Pending
- 2008-01-29 EP EP12153170A patent/EP2450368A1/en not_active Withdrawn
- 2008-01-29 MX MX2009008230A patent/MX2009008230A/es active IP Right Grant
- 2008-01-29 CA CA2677073A patent/CA2677073C/en active Active
- 2008-01-29 EP EP15153373.4A patent/EP2896630B1/en not_active Not-in-force
- 2008-01-29 KR KR1020147024226A patent/KR101722305B1/ko not_active Expired - Fee Related
- 2008-01-29 EP EP20110177630 patent/EP2423221B1/en not_active Not-in-force
- 2008-01-29 US US12/021,832 patent/US7884184B2/en active Active
- 2008-01-29 CN CN201610958012.4A patent/CN107011431B/zh not_active Expired - Fee Related
- 2008-01-29 CN CN201310685046.7A patent/CN103755789B/zh not_active Expired - Fee Related
- 2008-01-29 EP EP12153164A patent/EP2450366A1/en not_active Withdrawn
- 2008-01-29 EP EP08713321.1A patent/EP2125883B2/en not_active Not-in-force
- 2008-01-29 EP EP11177634.0A patent/EP2423222B2/en not_active Not-in-force
- 2008-01-29 EP EP20110177625 patent/EP2423220B1/en not_active Not-in-force
- 2008-01-29 KR KR1020097017996A patent/KR20100014871A/ko not_active Ceased
- 2008-01-29 MX MX2015014429A patent/MX347197B/es unknown
- 2008-01-29 JP JP2009548278A patent/JP4866467B2/ja not_active Expired - Fee Related
- 2008-01-29 AT AT08713321T patent/ATE525392T1/de not_active IP Right Cessation
- 2008-01-29 EP EP20120153177 patent/EP2450372B1/en not_active Not-in-force
- 2008-01-29 WO PCT/US2008/001148 patent/WO2008094538A2/en not_active Ceased
- 2008-01-29 CA CA3001783A patent/CA3001783C/en active Active
- 2008-01-29 KR KR1020177008095A patent/KR20170037677A/ko not_active Ceased
- 2008-01-29 CA CA3034396A patent/CA3034396C/en active Active
- 2008-01-29 EP EP12153171A patent/EP2450369A1/en not_active Withdrawn
- 2008-01-29 CA CA3161849A patent/CA3161849A1/en active Pending
- 2008-01-29 CA CA2915168A patent/CA2915168C/en active Active
- 2008-01-29 EP EP12153173A patent/EP2450370A1/en not_active Withdrawn
- 2008-01-29 EP EP12153166A patent/EP2450367A1/en not_active Withdrawn
- 2008-01-29 CA CA2963138A patent/CA2963138C/en active Active
-
2009
- 2009-07-28 IL IL200129A patent/IL200129A/en active IP Right Grant
- 2009-07-30 MX MX2018015933A patent/MX2018015933A/es unknown
-
2010
- 2010-12-29 US US12/981,098 patent/US20110182921A1/en not_active Abandoned
-
2011
- 2011-11-11 JP JP2011247226A patent/JP5643739B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-30 JP JP2014154372A patent/JP6121369B2/ja not_active Expired - Fee Related
-
2015
- 2015-09-17 US US14/857,693 patent/US10213496B2/en active Active
-
2016
- 2016-05-04 IL IL245478A patent/IL245478B/en active IP Right Grant
-
2017
- 2017-03-29 JP JP2017064298A patent/JP6472476B2/ja not_active Expired - Fee Related
-
2018
- 2018-06-22 US US16/015,802 patent/US10925940B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,814 patent/US11045528B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,822 patent/US11045529B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,796 patent/US10925939B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,784 patent/US10751397B2/en active Active
- 2018-06-22 US US16/015,837 patent/US11045531B2/en not_active Expired - Fee Related
- 2018-06-22 US US16/015,828 patent/US11045530B2/en not_active Expired - Fee Related
- 2018-10-16 US US16/161,671 patent/US11045532B2/en not_active Expired - Fee Related
- 2018-10-16 US US16/161,674 patent/US10925941B2/en not_active Expired - Fee Related
-
2019
- 2019-01-22 JP JP2019008352A patent/JP2019089793A/ja active Pending
- 2019-03-04 US US16/291,372 patent/US10925942B2/en not_active Expired - Fee Related
- 2019-03-04 US US16/291,658 patent/US10980867B2/en not_active Expired - Fee Related
- 2019-06-10 IL IL267186A patent/IL267186B/en active IP Right Grant
- 2019-08-02 US US16/530,104 patent/US20190351036A1/en not_active Abandoned
-
2021
- 2021-01-28 JP JP2021011596A patent/JP2021073255A/ja not_active Withdrawn
- 2021-04-21 US US17/236,463 patent/US11844826B2/en active Active
- 2021-04-21 US US17/236,534 patent/US12016909B2/en active Active
- 2021-04-22 JP JP2021072446A patent/JP2021107443A/ja active Pending
- 2021-04-22 JP JP2021072455A patent/JP2021107444A/ja active Pending
-
2022
- 2022-01-14 US US17/576,321 patent/US20220211827A1/en not_active Abandoned
- 2022-09-29 JP JP2022155804A patent/JP2022177270A/ja active Pending
-
2024
- 2024-03-06 JP JP2024033497A patent/JP2024059975A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017165733A5 (enExample) | ||
| AR127116A2 (es) | Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores | |
| EA201790953A1 (ru) | Изменение экспрессии гена в cart-клетках и их применения | |
| RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| MX395287B (es) | Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos. | |
| EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
| EP4289484A3 (en) | Anti-ctla-4 antibodies and methods of use thereof | |
| FI2884999T4 (fi) | Menetelmä ja koostumuksia soluimmunoterapiaa varten | |
| JP2010516290A5 (enExample) | ||
| PE20181490A1 (es) | Tratamientos contra el cancer de utero | |
| JP2017538401A5 (enExample) | ||
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| MX386060B (es) | Composiciones y usos para inmunoterapia. | |
| MX392416B (es) | Métodos y composiciones para terapia celular adoptiva. | |
| WO2015193359A3 (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll) | |
| WO2015112749A3 (en) | Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy | |
| WO2015112626A8 (en) | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules | |
| WO2015142675A8 (en) | Treatment of cancer using chimeric antigen receptor | |
| WO2011113819A3 (en) | Diagnosis and treatment of cancer based on avl9 | |
| JP2017501211A5 (enExample) | ||
| WO2016173605A8 (en) | Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof | |
| JP2018023397A5 (enExample) | ||
| PE20181897A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cancer | |
| MX2020003129A (es) | Composiciones celulares que comprenden linfocitos t específicos para antígenos para una terapia adoptiva. | |
| WO2017203370A3 (en) | Cmv epitopes |